The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
Lisa M Force, Jonathan M Kocarnik, Miranda L May, Kayleigh Bhangdia, Andrew Crist, Louise Penberthy, Natalie Pritchett, Alistair Acheson, Lee Deitesfeld, Bhoomadevi A, Hasan Aalruz, Nasir Abbas · 2025
Read The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 by Lisa M Force, Jonathan M Kocarnik, Miranda L May, Kayleigh Bhangdia, Andrew Crist, Louise Penberthy, Natalie Pritchett, Alistair Acheson, Lee Deitesfeld, Bhoomadevi A, Hasan Aalruz, Nasir Abbas (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w4414590999.txt.
Description
Lisa Force, Jonathan Kocarnik, Miranda May, and the GBD 2023 Cancer Collaborators estimate the global burden of cancer. Their analysis appeared in The Lancet in 2025. Many countries lack current cancer surveillance data. Policy still needs accurate numbers.
The team modelled forty-seven cancer types across two hundred four countries, from 1990 to 2023. In 2023 there were about eighteen and a half million new cases and over ten million deaths. Cancer ranked second only to cardiovascular disease as a cause of death. Most cases and deaths fell in poorer countries. About two fifths of deaths traced to known risk factors. The study also forecasts the burden through 2050.
Catalog record
| CREATOR | Lisa M Force, Jonathan M Kocarnik, Miranda L May, Kayleigh Bhangdia, Andrew Crist, Louise Penberthy, Natalie Pritchett, Alistair Acheson, Lee Deitesfeld, Bhoomadevi A, Hasan Aalruz, Nasir Abbas |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 115 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / The Lancet |